Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -96.49% is 49% above its 5-year average of -190.40%, near the high end of its 5-year range (-353.96%–-96.40%).
11.68% above its 12-month average of -109.25%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -29.05%.
RETURN ON ASSETS (ROA)
-96.49%
RETURN ON ASSETS (ROA) AVG TTM
-109.25%
RETURN ON ASSETS (ROA) AVG 3Y
-126.41%
RETURN ON ASSETS (ROA) AVG 5Y
-190.40%
RETURN ON ASSETS (ROA) AVG 10Y
-186.49%
RETURN ON ASSETS (ROA) AVG 15Y
-147.02%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+11.68%
CURRENT VS 3Y AVG
+23.67%
CURRENT VS 5Y AVG
+49.32%
CURRENT VS 10Y AVG
+48.26%
CURRENT VS 15Y AVG
+34.37%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.05%
median of 764 covered companies
CURRENT VS SECTOR MEDIAN
-210.81%
vs the sector median at left
TuHURA Biosciences, Inc.
Market Cap
$121.95M
Return on Assets (ROA)
-96.49%
TTM Avg
-109.25%
3Y Avg
-126.41%
5Y Avg
-190.40%
Market Cap
$121.75M
Return on Assets (ROA)
-31.33%
TTM Avg
-56.73%
3Y Avg
-59.49%
5Y Avg
-64.55%
Market Cap
$122.26M
Return on Assets (ROA)
-1.70%
TTM Avg
-35.34%
3Y Avg
-51.03%
5Y Avg
-36.99%
Market Cap
$121.01M
Return on Assets (ROA)
-26.48%
TTM Avg
-24.24%
3Y Avg
-21.83%
5Y Avg
-17.99%
Market Cap
$123.16M
Return on Assets (ROA)
-49.93%
TTM Avg
-95.40%
3Y Avg
-72.70%
5Y Avg
-57.07%
Market Cap
$125.34M
Return on Assets (ROA)
-68.74%
TTM Avg
-454.56%
3Y Avg
-368.82%
5Y Avg
-586.69%
Market Cap
$118.52M
Return on Assets (ROA)
-53.26%
TTM Avg
-24.98%
3Y Avg
-43.10%
5Y Avg
-143.56%
Market Cap
$126.43M
Return on Assets (ROA)
-87.44%
TTM Avg
-86.57%
3Y Avg
-87.06%
5Y Avg
-85.09%
Market Cap
$117.05M
Return on Assets (ROA)
-0.05%
TTM Avg
-38.03%
3Y Avg
-60.31%
5Y Avg
-59.32%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $121.95M | -96.49% | -109.25% | -126.41% | -190.40% |
| Cibus, Inc. (CBUS)vs › | $121.75M | -31.33% | -56.73% | -59.49% | -64.55% |
| enGene Holdings Inc. (ENGN)vs › | $122.26M | -1.70% | -35.34% | -51.03% | -36.99% |
| Seer, Inc. (SEER)vs › | $121.01M | -26.48% | -24.24% | -21.83% | -17.99% |
| Spruce Biosciences, Inc. (SPRB)vs › | $123.16M | -49.93% | -95.40% | -72.70% | -57.07% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.34M | -68.74% | -454.56% | -368.82% | -586.69% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.52M | -53.26% | -24.98% | -43.10% | -143.56% |
| Entera Bio Ltd. (ENTX)vs › | $126.43M | -87.44% | -86.57% | -87.06% | -85.09% |
| Coya Therapeutics, Inc. (COYA)vs › | $117.05M | -0.05% | -38.03% | -60.31% | -59.32% |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.03M | -72.42% | -66.03% | -45.57% | -48.77% |
ROA
-96.5%
ROE
-165.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -109.90% |
| 2024-12-31 | -108.59% |
| 2023-12-31 | -190.75% |
| 2022-12-31 | -96.40% |
| 2021-12-31 | -353.96% |
| 2021-06-30 | -282.79% |
| 2020-06-30 | -310.62% |
| 2019-06-30 | -199.35% |
| 2018-06-30 | -157.44% |
| 2017-06-30 | -102.16% |
| 2016-06-30 | -139.48% |
| 2015-06-30 | -168.82% |
| 2013-12-31 | -191.97% |
| 2012-06-30 | 0.00% |
| 2011-06-30 | 0.00% |
| 2010-06-30 | 0.00% |
